BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20073611)

  • 1. Expression of JL1 is an effective adjunctive marker of leukemia cutis.
    Park YS; Park SH; Park SJ; Kim Y; Jang KT; Ko YH; Lee MW; Huh JR; Park CS
    Arch Pathol Lab Med; 2010 Jan; 134(1):95-102. PubMed ID: 20073611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in
    Park SH; You E; Park CJ; Jang S; Cho YU; Yoon CH; Koh KN; Im HJ; Seo JJ
    Ann Lab Med; 2019 Jul; 39(4):358-366. PubMed ID: 30809981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD99 (p30/32MIC2) immunoreactivity in the diagnosis of leukemia cutis.
    Dorfman DM; Kraus M; Perez-Atayde AR; Barnhill RL; Pinkus GS; Granter SR
    Mod Pathol; 1997 Apr; 10(4):283-8. PubMed ID: 9110288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of JL1 in Burkitt lymphoma is associated with improved overall survival.
    Hwang I; Go H; Jeon YK; Ko YH; Yoon DH; Suh C; Huh JR; Lee H; Gil M; Park CS
    Virchows Arch; 2011 Oct; 459(4):353-9. PubMed ID: 21814778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria.
    Kaddu S; Zenahlik P; Beham-Schmid C; Kerl H; Cerroni L
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):966-78. PubMed ID: 10365929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of immunohistochemistry in the diagnosis of leukemia cutis: study of 54 cases using paraffin-section markers.
    Ratnam KV; Su WP; Ziesmer SC; Li CY
    J Cutan Pathol; 1992 Jun; 19(3):193-200. PubMed ID: 1383298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma.
    Kim MS; Park CJ; Cho YU; Jang S; Seo EJ; Park CS; Huh J; Im HJ; Seo JJ; Yoon DH; Suh C
    Ann Lab Med; 2020 Jan; 40(1):1-6. PubMed ID: 31432632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic potential of JL1, a thymocyte surface protein, for leukemia.
    Kim TJ; Park SH
    J Korean Med Sci; 1998 Oct; 13(5):455-8. PubMed ID: 9811172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemia cutis as the presenting symptom of acute myeloid leukemia: report of three cases.
    Moyer AB; Rembold J; Lee NE; Johnson G; Gardner JM
    Dermatol Online J; 2018 May; 24(5):. PubMed ID: 30142735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD30 Expression Is Rare in Myeloid Leukemia Cutis: A Study of 55 Cases and Implications for Routine Diagnostic Algorithms.
    Ogunrinade O; Terrano D; Chiu A; Pulitzer M
    Am J Dermatopathol; 2017 May; 39(5):351-357. PubMed ID: 27893466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias.
    Park WS; Bae YM; Chung DH; Kim TJ; Choi EY; Chung JK; Lee MC; Park SY; Park MH; Park SH
    Leukemia; 1998 Oct; 12(10):1583-90. PubMed ID: 9766503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of leukemia-associated antigen, JL1, in bone marrow and thymus.
    Shin YK; Choi EY; Kim SH; Chung J; Chung DH; Park WS; Jung KC; Kim HS; Park S; Kim HJ; Park MH; Min CK; Kim CC; Park SH
    Am J Pathol; 2001 Apr; 158(4):1473-80. PubMed ID: 11290565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemia cutis. Analysis of 50 biopsy-proven cases with an emphasis on occurrence in myelodysplastic syndromes.
    Longacre TA; Smoller BR
    Am J Clin Pathol; 1993 Sep; 100(3):276-84. PubMed ID: 8379536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemia cutis from CD56 positive, myeloperoxidase negative acute myeloid leukemia.
    Abdou AG; Seleit I; Bakry OA; Abdel-Wahed MM
    Acta Dermatovenerol Croat; 2013; 21(3):189-92. PubMed ID: 24183224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the JL1 epitope, which encompasses the nonglycosylation site of CD43, as a marker of immature/neoplastic Langerhans cells.
    Park HJ; Jeon YK; Lee AH; Oh YH; Park SH; Jung KC
    Am J Surg Pathol; 2012 Aug; 36(8):1150-7. PubMed ID: 22790855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of myeloperoxidase stain in the differential diagnosis of leukemia cutis vs. hystiocitoid Sweet syndrome.
    Valerón-Almazán P; Bastida J; Vilar J; Santana N; Medina C; Carretero G
    Dermatol Online J; 2011 Apr; 17(4):11. PubMed ID: 21549086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JL1, a novel differentiation antigen of human cortical thymocyte.
    Park SH; Bae YM; Kwon HJ; Kim TJ; Kim J; Lee SJ; Lee SK
    J Exp Med; 1993 Oct; 178(4):1447-51. PubMed ID: 8376947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERG Is a Useful Immunohistochemical Marker to Distinguish Leukemia Cutis From Nonneoplastic Leukocytic Infiltrates in the Skin.
    Xu B; Naughton D; Busam K; Pulitzer M
    Am J Dermatopathol; 2016 Sep; 38(9):672-7. PubMed ID: 26909589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric aleukemic leukemia cutis: report of 3 cases and review of the literature.
    Gru AA; Coughlin CC; Schapiro ML; Lombardi M; Martin A; Bayliss SJ; Frater J; Dehner LP
    Am J Dermatopathol; 2015 Jun; 37(6):477-84. PubMed ID: 25148106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, histopathologic, and immunohistochemical correlations in leukemia cutis.
    Su WP
    Semin Dermatol; 1994 Sep; 13(3):223-30. PubMed ID: 7986692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.